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Abstract
Background: Inbreeding and population bottlenecks in the ancestry of Friesian horses has led to health issues such
as dwarfism. The limbs of dwarfs are short and the ribs are protruding inwards at the costochondral junction, while
the head and back appear normal. A striking feature of the condition is the flexor tendon laxity that leads to
hyperextension of the fetlock joints. The growth plates of dwarfs display disorganized and thickened chondrocyte
columns. The aim of this study was to identify the gene defect that causes the recessively inherited trait in Friesian
horses to understand the disease process at the molecular level.
Results: We have localized the genetic cause of the dwarfism phenotype by a genome wide approach to a 3 Mb
region on the p-arm of equine chromosome 14. The DNA of two dwarfs and one control Friesian horse was
sequenced completely and we identified the missense mutation ECA14:g.4535550C > T that cosegregated with the
phenotype in all Friesians analyzed. The mutation leads to the amino acid substitution p.(Arg17Lys) of xylosylprotein
beta 1,4-galactosyltransferase 7 encoded by B4GALT7. The protein is one of the enzymes that synthesize the
tetrasaccharide linker between protein and glycosaminoglycan moieties of proteoglycans of the extracellular matrix.
The mutation not only affects a conserved arginine codon but also the last nucleotide of the first exon of the gene
and we show that it impedes splicing of the primary transcript in cultured fibroblasts from a heterozygous horse. As a
result, the level of B4GALT7 mRNA in fibroblasts from a dwarf is only 2 % compared to normal levels. Mutations in
B4GALT7 in humans are associated with Ehlers-Danlos syndrome progeroid type 1 and Larsen of Reunion Island
syndrome. Growth retardation and ligamentous laxity are common manifestations of these syndromes.
Conclusions: We suggest that the identified mutation of equine B4GALT7 leads to the typical dwarfism phenotype in
Friesian horses due to deficient splicing of transcripts of the gene. The mutated gene implicates the extracellular matrix
in the regular organization of chrondrocyte columns of the growth plate. Conservation of individual amino acids may
not be necessary at the protein level but instead may reflect underlying conservation of nucleotide sequence that are
required for efficient splicing.
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Background
A dwarfism trait has been segregating in the Friesian
horse breed for decades [1], (OMIA 000299-9796 [2]).
Characteristic for the trait is the physeal growth retard-
ation of limbs and ribs, resulting in a disproportionate
form of dwarfism. The affected horses exhibit hyper-
extension of the fetlock joints of all limbs with varying
severity. Flexor tendon laxity, which is often seen in
newborn foals of all breeds, fails to recover in dwarf
foals and instead tends to increase further during aging.
As a consequence, these dwarf Friesians develop an ab-
normal gait in which the limbs undergo extreme out-
ward rotation at the level of carpus and hocks. The
ribcage is abnormal in most cases with thickened and
S-shaped costochondral junctions, leading to an inward
protrusion of the chest at the level of Th10-16 (Fig. 1b,c).
Mature dwarfs have a head of the same size as un-
affected horses, a broader chest with narrowing at the
costochondral junction, a disproportionally long back
and abnormally short limbs. The abdomen has a weak
and rounded appearance, and the musculature over the
body is poorly developed. Involvement of the hypothalamic-
pituitary growth axis in the pathogenesis of the condition
has been excluded [3].
A monogenic recessive mode of inheritance is most
likely and, considering the breed structure with a small
number of founders and narrow population bottlenecks,
it is expected that the dwarfs are homozygous for the
responsible gene mutation [4]. A genome wide associ-
ation study of 10 cases and 10 control Friesian horses
has been reported earlier [4]. The dwarfism locus was
assigned to the telomeric region of the p-arm of
chromosome 14 (ECA14), although genome wide signifi-
cance was not reached. The aim of the present study
was to confirm and further define the critical chromo-
some region of the locus and to identify the responsible
gene mutation. The identification of the gene enables
the comparison of the phenotype across species and
enhances the understanding of the processes of growth
and development.
Results
Gene mapping
To substantiate the localization of the dwarfism gene on
chromosome ECA14 we performed a genome wide com-
parison of a group of dwarfs with a group of controls
from the Friesian horse breed. The allelic association
reached genome wide significance in the telomeric re-
gion of the p-arm of ECA14 with a Bonferroni corrected
Pgenome = 2.90 × 10−19 for BIEC2-239391 at position
3776009, the SNP that was most significantly associated
with dwarfism (Fig. 2a). In total 35 SNPs passed the
Bonferroni corrected significance level (1.68 × 10−6) and
all were located on ECA14 between positions 1 and
9510581. Inspection of the genotypes of the individual
horses in the region showed that only the dwarfs shared
a haplotype of 3 Mb homozygously, confirming that the
phenotype originated from a single founder (Fig. 2b).
The genotypes clearly pointed to recombination events
that were evident in several cases and that placed the
critical region between positions 3151847 and 6229282
on ECA14. According to the annotation release 101 of
the NCBI of the equine reference genome the critical
region contained 66 genes [5].
DNA sequence analysis
Full genome DNA sequence data was generated of four
dwarfs and three control Friesian horses by Next Gener-
ation Sequencing. The DNA sequence of the critical
region of ECA14 of the dwarfs was compared with those
of the controls, the reference genome, and the Quarter
Horse that is publicly available [6]. As dwarfism has not
been reported in the Quarter Horse breed we assumed
that the causative mutation is not present in this popula-
tion and that the horse was homozygous for the refer-
ence allele. The variations of the dwarfs as compared
with the reference genome were filtered by snpSift [7]
for possible effects on amino acid sequence or splicing
(Additional file 1). Using the Integrative Genomics
Viewer [8] we then searched for the variations that were
absent in the Quarter Horse and not homozygously
present in the control Friesian horses. Only one
nonsynonymous mutation fulfilled these criteria. The
mutation was ECA14:g.4535550C > T in B4GALT7
and corresponds to XM_014730464.1:c.50G > A and
XP_014585950.1:p.(Arg17Lys). Arginine and lysine
are both basic amino acids that are interchangeably
seen in many conserved protein domains. In this
case, however, the arginine residue at position 17 of
the equine B4GALT7 encoded protein xylosylprotein
Fig. 1 Dwarfism in the Friesian horse breed. a A female dwarf next
to two normal female Friesian horses. The dwarf has a height at the
withers of 1.12 m; the horse in the middle has a height of 1.54 m,
which is close to the minimum allowed by the breed standard (1.53 m);
the horse on the right has a height of 1.66 m. b and c Photographic
illustrations of the typical pectus excavatum phenotype in the Friesian
dwarf of the right b and the left side c
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beta 1,4-galactosyltransferase, polypeptide 7 (galacto-
syltransferase I) is strictly conserved in all verte-
brates analyzed (Fig. 3a). Nonetheless, the mutation
was considered moderate by the snpSift analysis and
benign by PolyPhen-2 [9].
The association of the mutation with the dwarfism
phenotype was evaluated by Sanger DNA sequencing.
All 29 dwarfs of which DNA was available were homozy-
gous for the mutation (Fig. 4c, line 2). The 8 obligate
carriers were heterozygous (line 3) and of a group of 177
Friesian horses 22 were carrier of the mutation and 155
were homozygous for the reference allele (line 1).
RNA analysis
The mutated guanosine nucleotide is the last residue of
exon 1 of B4GALT7 and the position of this first splice
donor relative to the start codon of the gene is con-
served in vertebrates (Fig. 3b). The nucleotide is second
in the triplet coding for arginine and since this amino
acid is conserved, the guanosine is conserved with it.
casescontrols
3.2 M
6.2 M
B4GALT7
a b
Fig. 2 Localization of the dwarfism locus in Friesian horses. a Manhattan plot of the genome wide association study. The DNA of 19 dwarfs and 65
controls of the Friesian horse breed was typed with the Illumina EquineSNP50 array. The allele frequency differences between the groups were
assessed with GenABEL software and plotted as the –log10p value from Chi-square tests. The red line indicates the Bonferroni corrected significance
level. b Homozygosity mapping. Individual genotypes of informative SNPs from the telomeric region (0 - 10 Mb) of ECA14 of cases and controls were
extracted from the array data. The results of the telomeric 134 SNPs of the p-arm that passed quality control are shown. Red: homozygous genotype
of major allele in the dwarfs; green: homozygous genotype of minor allele; yellow: heterozygous genotype. The region of homozygosity in the dwarfs
is bordered by the SNPs BIEC2-239119 and BIEC2-240544
a
b
Fig. 3 Conservation of B4GALT7. a Alignment of the N-terminal amino acid sequence of xylosylprotein beta 1,4-galactosyltransferase, polypeptide
7 of horse with that of several mammals, an amphibian and a fish. The protein sequences are derived from the reference cDNAs listed below. b
Alignment of the splice donor site of exon 1 of B4GALT7 of horse with that of other vertebrate species. The exon DNA sequence is in upper case
and that of the intron is in lower case. The residues in a and b that are mutated in Friesian horse dwarfs are underlined. Residues that are identical to
those in horse are indicated by a dot; gaps that are introduced to optimize the alignment are indicated by a dash. The exon 1/intron 1 splice junctions
are derived from the respective reference genomes and based on the following cDNA reference sequences. Horse (Equus caballus): XM_014730464;
human: NM_007255; cow (Bos taurus): NM_001075321; pig (Sus scrofa): NM_001168422; rhinoceros (Ceratotherium simum): XM_010145472; rat (Rattus
norvegicus): NM_001031661; bat (Eptesicus fuscus): XM_008143179; Dolphin (Tursiops truncatus): XM_004313659; frog [Xenopus (Silurana) tropicalis]:
(NM_001126545); zebrafish (Danio rerio): NM_001003417
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We wondered whether the selection pressure could have
worked the other way around; that is, that the nucleotide
itself was conserved not due to its amino acid coding
properties but due to its splicing function. The mutation
of guanosine to adenosine might affect splicing of the
primary RNA transcript of the gene and splicing require-
ments may block its propagation. According to the
splice site predictor NNSPLICE 0.9 [10] the exon 1/in-
tron 1 junction of the equine reference gene had a splice
donor score of 0.96 on a scale of 0 to 1. The mutated
nucleotide sequence of the dwarfs had a moderate score
of 0.58, suggesting that the mutation could indeed inter-
fere with splicing.
To investigate the effect of the mutation on splicing of
the primary transcript we isolated RNA from cultured
skin fibroblasts of a Friesian horse dwarf, of a heterozy-
gous carrier of the B4GALT7 mutation and of a Friesian
horse that was homozygous for the reference allele. Syn-
thesis of cDNA was followed by PCR with a forward
primer derived from B4GALT7 exon 1 and a reverse
primer from intron 1 or exon 2 (Fig. 4a). The RNA of
the wildtype horse and the heterozygous horse yielded a
splicing product with the exonic primers of the expected
length of 401 bp (Fig. 4b, lanes 2 and 3). This product
was less pronounced in the cDNA from the dwarf (lane
4). The primer set that included the intron 1 reverse pri-
mer produced a cDNA band derived from unspliced
RNA of approximately 220 bp. This band was detected
with the samples from the heterozygous horse and from
the dwarf (lanes 6 and 7), but also, be it weakly, with the
sample from the wildtype horse (lane 5). Combination of
the 3 primers in a semi quantitative PCR showed spliced
and unspliced products with similar intensities in the
cDNA from the dwarf (lane 11). The wild type horse and
the heterozygous horse do not display the unspliced prod-
uct of 220 bp with the 3 primer PCR (lanes 9 and 10).
When we analyzed the cDNA sequence of the
unspliced product from the heterozygous horse (lane 6)
it was derived from the mutant allele only (Fig. 4c, line
4). The cDNA sequence of the properly spliced product
from the same horse (lane 3) indicated that it was derived
from the normal allele (Fig. 4c, line 5). The B4GALT7
cDNA analysis confirms that the mutation r.50 g > a leads
to a splicing deficiency of the primary transcript.
The exon 1/exon 2 primer set produced minor frag-
ments that were larger than the expected length (Fig. 4b,
lane 4). DNA sequence analysis of the fragments derived
from the dwarf showed that the fragment of approximately
a
b c
Fig. 4 Mutation of the terminal nucleotide of exon 1 of B4GALT7 affects proper RNA splicing of intron 1. a Map of the exon 1- exon 2 region of
the equine B4GALT7 gene. The positions of the exons 1 and 2 are indicated by numbered boxes; α: alternative exon; γ: cryptic exon. The position
of the used PCR primers are indicated by > and < signs with Roman numerals. I>: EX1F; <II: IN1R; <III: EX2R. b cDNA fragments derived from a
Friesian horse homozygous for the reference allele (lanes 2, 5 and 9), a heterozygous carrier (lanes 3. 6 and 10) and a Friesian horse dwarf (lanes
4, 7 and 11). Fibroblasts were grown from skin biopsies from the horses and RNA was isolated. cDNA was synthesized with reverse transcriptase
followed by PCR with equine B4GALT7 specific primers. Lanes 1 and 8: 100 bp size standard ladder (2 = 200 bp fragment, 4 = 400 bp fragment);
lanes 2-4: primers I and II; lanes 5-7: primers I and III; lanes 9-11: primers I, II and III. c Genomic DNA and RNA sequence analysis of B4GALT7
fragments from a horse homozygous for the reference allele (G/G), a dwarf (A/A) and a heterozygous carrier (G/A). The arrow indicates the
position of the mutation. Sub: substrate genomic DNA (DNA) from the horses representing the three genotypes (gen) or cDNA synthesized with
RNA from fibroblasts of the heterozygous horse (RNA). Pri: The PCR fragments were generated with primer I and either primer II or III as indicated.
The mutant allele A is only observed in the unspliced RNA fragment (line 4) while the properly spliced product from the same heterozygous
horse only shows the reference allele G (line 5)
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560 bp contained an alternative exon of 162 nucleotides be-
tween exon 1 and exon 2 sequences that were spliced at
the proper positions. This alternative exon is annotated as
such in Genbank. It is situated from position 4533657 to
4533818 of chromosome 14 of the reference genome
EquCab 2.0. It should be noted that the gene is situated in
the reverse orientation on the chromosome. The alternative
exon has an open reading frame that is in frame with the
remainder of the coding sequence of the gene and the
amino acid sequence encoded by the exon is conserved in
mammals.
Another minor cDNA fragment of approximately
730 bp contained the same alternative exon sequence to-
gether with a cryptic exon of 169 nucleotides located
between exon 1 and the alternative exon. The genomic
location of the cryptic exon was from 4534375 to
4534543 on chromosome 14 and it contained multiple
stopcodons in frame with the start codon on exon 1.
The aberrant splicing from the exon 1 donor due to
the variant r.50 g > a was associated with a severe reduc-
tion of expression of B4GALT7 at the mRNA level.
Quantitative PCR measurement of cDNA fragments
indicated that the concentration of transcripts from the
gene in the fibroblasts from the dwarf was only 2 % of
that in fibroblasts from a Friesian horse that did not
carry the mutation (Additional file 2).
Discussion
Disproportionate dwarfism in Friesian horses is associ-
ated with a mutation in B4GALT7. The mutation
changes a conserved arginine codon to a lysine codon.
Both amino acid residues are basic and the effect of the
mutation is considered moderate by the snpSift predic-
tion. The mutation also affects the last nucleotide of
exon 1 of the gene. Unspliced cDNA fragments spanning
the exon 1/intron 1 junction can be detected regardless
of the genotype of the horses. However, the cDNA
sequences from a heterozygous horse clearly show that
RNA derived from the mutant allele is hardly spliced, in
contrast to the RNA from the normal allele (Fig. 4c,
lines 4 and 5).
When an exonic and an intronic reverse primer are
allowed to compete in a 3 primer PCR, only the cDNA
from the dwarf displays the spliced and unspliced prod-
ucts in comparable amounts (Fig. 4b, lane 11). The nor-
mally spliced product is seen prominently in the wild
type horse and the horse heterozygous for the mutation,
but the unspliced product cannot be discerned among
the products from these horses (lanes 9 and 10). This
semi quantitative PCR and the cDNA sequence analysis
of the products of the heterozygous horse confirms that
the B4GALT7 mutation strongly reduces the splicing
capacity of the exon 1/intron 1 junction.
In the homozygous state, the mutation leads to low
mRNA levels and the expression of the gene is strongly
reduced as measured by qPCR. The improperly spliced
transcripts could be prone to nonsense mediated decay.
The nucleotide sequence AGgt of the exon 1 splice
junction of B4GALT7 and its position with regard to the
start codon are highly conserved (Fig. 3b). One could
argue that the last nucleotide of the exon is expected to
be conserved if the encoded arginine residue would be
essential for the function of the protein. This G residue
is the second nucleotide of the codon and all six triplets
that code for arginine have a G residue at the second
position. Thus, if the arginine is conserved, the guano-
sine is conserved with it. The first position of the codon
under consideration is a conserved A residue, while 4 of
the 6 possible arginine codons start with a C. A func-
tional restriction on the encoded arginine residue would
therefore not necessarily lead to conservation of the A
residue of the AGgt splice junction. The hypothetical
mutation of the A residue to a C would only lead to a
moderate drop of the splice donor score from 0.96 to
0.89. According to this prediction a mutation of the sec-
ond to last A residue to a C would be allowed while in
fact it is highly conserved. Recently, a mutation of the A
residue of a splice donor site in IBA57 with the same
AGgt junction sequence as exon 1 of B4GALT7 was
shown to impede proper splicing, causing a severe
leukoencephalopathy [11]. This mutation did not alter
the encoded amino acid and it stresses the importance
of the exonic terminal nucleotide sequences for splicing
at particular junctions. An in vitro splicing assay may
resolve the importance of the second to last A residue of
the exon 1 of B4GALT7 for proper splicing. Concurrent
with our results, the NNSPLICE program assigns a
much lower splice donor score of 0.58 for the mutation
found in the Friesian dwarfs. Considering all our results,
we conclude that the conservation of the exon 1
terminal sequence in vertebrates reflects a restriction on
a splicing requirement rather than on a functional re-
quirement of the encoded amino acid. Characterization
of naturally occurring mutations that are uncovered
because of an association with disease can render im-
portant insights in splicing requirements [12].
In humans, mutations in B4GALT7 cause the Ehlers-
Danlos syndrome, progeroid type 1 (EDSP1, OMIM130070)
and Larsen of Reunion Island syndrome (LRS). Only 7 mu-
tations have been described in relation to the recessively
inherited syndromes [13–18]. Most patients were normal
with respect to length and weight at birth but soon were
presented with growth retardation, osteopenia, facial
dysmorphology, loose joints, bone dysplasias, loose
skin and in most cases mild forms of mental retard-
ation. Pectus carinatum was reported for a number of
patients [16, 17]. The human phenotype is highly
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variable, even in patients sharing the same mutation
homozygously [17].
A founder effect in a closed population of Reunion has
led to at least 22 cases of LRS that were genetically con-
firmed. LRS was described as a subtype of Larsen syn-
drome [19]. The same mutation that causes LRS was
observed homozygously in two siblings from another
population diagnosed with EDSP1. The progeroid
aspect was not observed in any of the genetically
confirmed cases of EDSP1 nor LRS and it has been
suggested to remove this term from the name of the
EDSP1 syndrome [16, 18].
Clear similarities between the conditions in man and
horse are growth retardation and hypermobile joints. Rib
deformities have been observed in human as well as
equine cases [1, 16, 17]. Pectus carinatum, reported in
human cases, refers to the pectus in which the ribcar-
tilage has been overdeveloped outward, leading to a
‘chicken chest’. In the Friesian horse cases on the
other hand, the ribcartilage has been overdeveloped
inward, leading to pectus excavatum or ‘shoemaker
chest’ in humans.
The dwarfism in the horse is described as a dispropor-
tionate growth disturbance because all limbs are short,
while the head and back appear rather normal. In con-
trast, almost all confirmed human patients with LRS and
EDSP1 display facial dysmorphism and disproportional
growth was not noted [16, 17]. Cognitive functions do
not seem to be impaired in dwarf horses. Another clear
difference between the phenotype in man and horse is
that loose skin has never been observed in Friesian
dwarfs. Atrophic scarring and/or delayed wound healing
has been reported for a number of human patients but
is never seen in Friesian horse dwarfs. The fibroblasts
from one human patient displayed reduced proliferation
rates [20], while the fibroblasts of the Friesian dwarf pro-
liferated at least as fast as the fibroblasts from normal
Friesians. The differences in the clinical presentations
between human patients and Friesian dwarfs may be due
to the nature of the mutation in horses, which we think
has predominantly an effect on the expression level of a
normally functioning protein. On the other hand, the
protein may have rate limiting key roles in processes that
are different in the two species, such that loss of activity
becomes manifest in different ways.
The B4GALT7 gene is highly expressed in the prolifer-
ative zone of the growth plate in rat [16]. Deficiency of
the encoded xylosylprotein beta-1,4-galactosyltransferase
7 apparently induces the irregularities of the chondro-
cyte columns seen in the growth plate of Friesian dwarfs
[1]. The enzyme adds the second of four saccharides that
form the linker between the protein core and the glycos-
aminoglycan moiety of proteoglycans. Proteoglycans are
major components of molecular networks of the
extracellular matrix. Mutations in any of the enzymes
that build the saccharide linker cause a variety of rare
syndromes with overlapping features, which are called
linkeropathies (reviewed in [21]). Dwarfism in Friesian
horses could therefore be considered as a new presenta-
tion of a linkeropathy.
Remarkably, this is the second gene with a role in
protein glycosylation in which we found a pathogenic
mutation in Friesian horses. Earlier we found a nonsense
mutation in B3GALNT2 involved in muscular dystrophy
with hydrocephalus in stillborn foals [22]. The encoded
beta-1,3-N-acetylgalactosaminyltransferase is involved in
glycosylation of alpha-dystroglycan, which is part of the
complex that connects the cytoskeleton with the extra-
cellular matrix.
Conclusions
We provide evidence indicating that dwarfism in
Friesian horses could be caused by a splicing deficiency
of B4GALT7 that severely reduces expression of the
gene. The conservation of the affected nucleotide
reflects a splicing requirement rather than a functional
requirement of the encoded amino acid. The clinical pic-
ture of the Friesian horse dwarfs adds to the phenotypic
variability observed in human patients with B4GALT7
mutations. Crosses between carriers can be prevented by
screening breeding horses for the B4GALT7 mutation
and the dwarfism trait could thus be eliminated from
the breed.
Methods
Phenotypes, genotypes and genome-wide association study
Friesian horses (n = 29) were diagnosed as being dwarfs
by local equine veterinarians in consultation with the
Equine Clinic of Utrecht University, usually via a digital
in vivo picture for confirmation of the phenotype.
Thirteen of the horses were male, 11 female and the sex
of 5 dwarfs was unknown. The group of unaffected con-
trols (n = 65) were Friesian horses without the character-
istic appearance of dwarfism [1]. In addition, we
obtained blood samples for DNA isolation from 8
parents of dwarfs and DNA samples from 177 Friesian
horses that were part of a DNA bank maintained at the
Dr. Van Haeringen Laboratory B.V..
Blood samples were taken and DNA was isolated as
described by Orr et al. [4]. Genotypes of 19 dwarfs
and 65 controls were obtained using the Illumina®
EquineSNP50 Genotyping BeadChip containing 54,602
SNPs. Quality control was performed using the
check.marker function in the GenABEL package in R
[23]. SNPs with MAF <5 % and call-rate <90 % were
discarded, leaving 29,840 SNPs (54.7 % of all SNPs)
for the analysis.
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The ccfast function in GenABEL package in R [23]
was used to determine the significance of allelic differ-
ences between dwarfs and unaffected horses with a
χ2-test (1df ). The Bonferroni corrected significance level
applied was 1.68 × 10−6. Homozygosity mapping in the
significantly associated region was performed by eye
to identify overlapping regions of homozygosity be-
tween dwarfs.
Genome sequencing
Four dwarf cases and three unrelated control were
paired-end sequenced with 150 nucleotide reads for the
full genome on Illumina NextSeq500 to an average
coverage of 4-9x according to the manufacturers proto-
cols. To increase the power to detect causal candidate
variants as a fully homozygous variant, we merged the
data for the four cases yielding an mean coverage of 36x.
The Illumina data was processed with our inhouse de-
veloped pipeline v 1.2.1 [24] including GATK v3.2.2 [25]
according to the best practices guidelines [26]. Briefly,
we mapped the pairs with BWA-MEM v0.7.5a [27],
marked duplicates, merged lanes, realigned indels. Base
recalibration did not improve our results, so this step
was skipped. Next, GATK Haplotypecaller was used to
call SNPs and indels. Variants are flagged as PASS only if
they do not meet the following criteria: QD < 2.0, MQ<
40.0,FS > 60.0, HaplotypeScore > 13.0, MQRankSum< -12.5,
ReadPosRankSum< -8.0, snpclusters > =3 in 35 bp. For
indels: QD< 2.0, FS >200.0, ReadPosRankSum< -20.0.
Detecting recessive candidate variants was done with
snpSift [28] fitting the model of reference or potential
carrier status in the control and homozygous state in the
cases. Moreover, coverage > 10, a genotypequality of >30
and effect impact ‘HIGH’ or ‘MODERATE’ was required.
Additional evaluation of the variant of interest was per-
formed with PolyPhen-2 [9].
The observed possibly detrimental DNA variant of
B4GALT7 was confirmed and evaluated in the complete
cohort by Sanger sequencing of PCR fragments. The
PCR primer sequences were 5’- AGTTTCTCGGAG
TGTAGAG-3’ (UP1F) and 5’-AGAGACATAGACCCTC
AGAG-3’ (IN1R). The PCR was performed with 50 ng
genomic DNA, 3 U Platinum Taq DNA polymerase
(Thermo Fisher Scientific, Waltham, MA), 2 mM
MgCl2, 0.2 mM each dNTP, 0.5 μM each primer, 1 M
betaine and 1× Platinum buffer. Temperature cycling
conditions were 5 min at 95 °C, 35 cycles of 30 s at 95 °
C, 30 s at 55 °C, 30 s at 72 °C, and a final elongation step
at 72 °C for 10 min. All amplifications were performed
on an ABI 9700 Thermal Cycler (Applied Biosystems,
Foster City, CA). The PRC primers were degraded by
addition of 1 U Exonuclease I (Thermo Fisher Scientific,
Waltham, MA) and incubation for 15 min. at 37 oC and
15 min. at 85 oC. DNA sequencing tercycle reactions
were performed using BigDye v3.1 (Thermo Fisher
Scientific, Waltham, MA) according to the manufac-
turer’s protocol. The products were analysed on a
3130XL Genetic Analyzer (Applied Biosystems, Foster
City, CA) and the data was analysed with Lasergene
(version 11 DNASTAR).
Homologous DNA and protein sequences from differ-
ent species were retrieved from GenBank and aligned
one by one by eye. Identities and differences were indi-
cated by using a word processor. The species were
selected arbitrary to represent close and distant mem-
bers of the animal kingdom.
RNA analysis
Fibroblasts were grown from 6 mm punch biobsies from
the skin of a dwarf, a carrier of the mutation of interest
and a Friesian horse homozygous for the reference allele.
The biopsies were washed in Euroflush (IMV technolo-
gies, L’Aigle, France) containing 5000 IU/ml heparin, cut
with scissors and incubated in petri dishes with DMEM/
M199 (1:1) medium containing pen/strep (10,000 U/ml
(all from Thermo Fisher Scientific, Waltham, MA),
2.5 ng/ml basic-FGF5 (Peprotech, Rocky Hill, NJ) and
20 % FCS at 38.5 oC with 5 % CO2 and 5 % O2. Prolifer-
ating fibroblasts were harvested and passaged in culture
flasks using standard procedures. RNA was isolated from
cultured fibroblasts with the RNeasy kit with an on-
column DNase digestion according to the instructions of
the manufacturer (Qiagen, Hilden, Germany). The RIN
value of the RNA was meausured with an Agilent 2100
Bioanalyzer (Santa Clara, CA, USA) and was found to be
9.5 or higher. cDNA was synthesized with the iScript kit
(Bio-Rad Laboratories, Hercules, CA) using 500 ng of
RNA in 20 μl reactions. Splicing products were PCR
amplified from 0.5 μl cDNA product with B4GALT7
exonic primers 5’-CTGGGAGCTCGAGCTCCATG-3’
(EX1F) and 5’-CTCAGGAAGCGGTGCATGTG-3’ (EX2R)
as described above. Unspliced products were amplified with
primer EX1F and the intronic primer IN1R described above.
In a semi quantitative experiment, the 3 primers were com-
bined in a single PCR using the same component concen-
trations and cycling conditions as above. The fragments
were visualized by electrophoresis on a 1 % agarose gel in
0.5x TBE with 0.5 μg/ml ethidium bromide followed by UV
irradiation of the gel.
For DNA sequence analysis and confirmation of the
origin of the products, the bands were cut from the gel
and the DNA was isolated with QIAquick gel extraction
kit (Qiagen, Hilden, Germany). The DNA sequencing
procedure was as described above.
Quantitative PCR for measurement of B4GALT7
transcripts was performed with forward primer 5’- G
ACGGCAGGTCCAGGTTG-3’ and reverse primer
5’- ACAGGCAACGAAGAGGTGG-3’ at an annealing
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temperature of 55 oC. The forward primer bridges exons 1
and 2, while the reverse primer is situated in exon 2. The
qPCR reactions contained 1x IQ SYBRGreen SuperMix
(Bio-Rad, Laboratories, Hercules, CA), 400 nM of each
primer and 1 μl cDNA, obtained as described above, in a
total volume of 15 μl. The reference genes were RPS19
and RPL13A, which were analyzed as described [29]. The
reactions were performed in a MyiQ2 thermal cycler and
the data was analyzed with IQ5 software (both from Bio-
Rad, Laboratories, Hercules, CA).
Additional files
Additional file 1: Variants with predicted moderate or high effect on
gene function in the critical chromosome region of Friesian dwarf horses.
Output of snpSift analysis of Next Generation Sequence data. (XLSX 15 kb)
Additional file 2: Expression of B4GALT7 in relation to genotype. qPCR
data of B4GALT7 mRNA from fibroblasts. (XLSX 13 kb)
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